Our Values
Message
Corporate Philosophy
Corporate Branding
Sawai at a Glance
Transparency
Products
Quality Policy & Feature of Each Function
ESG Data（Related Content）New Window
Sustainability
Sustainability Initiatives
Our Approach
Integrated Report（Related Content）New Window
Our Humanistic Business
Corporate Profile
Corporate History
InvestorsNew Window
Nov. 14. 2018
IR "Summary of Financial Results for the 1st Half of FY2018"
IR "Financial Results for the 1st Half of FY 2018"
Oct. 24. 2018
Upsher-Smith Launches Generic Version of ONFI® (Clobazam), CIV In Tablet And Oral Suspension Dosage Forms
Sep. 21. 2018
Sawai Pharmaceutical Receives Public Knowledge-Based Applications for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication
Sep. 05. 2018
MHLW Approves New Indication for ARIPIPRAZOLE Tablets 3 mg / 6 mg / 12 mg / 24 mg [SAWAI] and ARIPIPRAZOLE Oral Solution 3 mg / 6 mg / 12 mg Packet [SAWAI]
Sep. 03. 2018
Upsher-Smith Launches Generic Version of Lomotil® (Diphenoxylate Hydrochloride and Atropine Sulfate) Tablets
Aug. 16. 2018
Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs
Aug. 14. 2018
IR "Summary of Financial Results for the 1st Quarter of FY2018"
IR "Financial Results for the 1st Quarter of FY2018"
Aug. 08. 2018
Upsher-Smith Launches Bexarotene Capsules
Jul. 17. 2018
Upsher-Smith Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone™
Jun. 20. 2018
Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment
Jun. 14. 2018
Sawai Pharmaceutical Launches 7 Compounds with 17 Strengths of Generic Drugs
Jun. 06. 2018
MHLW approves New Indication for OSELTAMIVIR Capsules 75 mg [SAWAI] / Dry Syrup 3% [SAWAI]
May. 25. 2018
Sawai Pharmaceutical Submits Public Knowledge-Based Application for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication
May. 15. 2018
Announcement on Personnel Changes
IR "Medium-Term Business Plan (M1 TRUST 2021)"
IR "Summary of Financial Results for FY 2017"
IR "Financial Results for FY 2017"
May. 10. 2018
Upsher-Smith Launches Doxazosin Tablets, USP
Apr. 04. 2018
MHLW approves New Indication for OLANZAPINE formulation and New Administration for MEROPENEM formulation
Mar. 26. 2018
Announcement on Organizational Changes and Personnel Changes
Mar. 20. 2018
MHLW approves New Indication for PRAMIPEXOLE HYDROCHLORIDE Tablets 0.125 mg “SAWAI” / 0.5 mg “SAWAI”
Feb. 15. 2018
Sawai Pharmaceutical receives approvals for 8 compounds with 19 strengths of generic drugs
